← Oncology Approval Tracker

FDA DECISION ·

Tevimbra + platinum and fluoropyrimidine

tislelizumab-jsgr with platinum and fluoropyrimidine chemotherapy · BeiGene

FDA approvalNew or expanded indicationGastric and gastroesophageal junction cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line combination treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 at a score of at least 1.

LAMPGEN ANALYSIS

Why it matters

This action added a biomarker-defined gastric and junctional indication to the checkpoint inhibitor’s earlier esophageal label.

What research teams should watch

Keep the applicable PD-L1 scoring method and the HER2 result with the first-line treatment record.

PRIMARY RECORDS

Sources